Atrial Fibrillation Clinical Trial
Official title:
Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia that occurs after
on pump coronary artery bypass graft (CABG) surgery. It is associated with postoperative
complications, including increased risk of stroke, prolonged hospital stay and increased
costs.
Objectives: The aim of this study was to find reliable, effective, safe and well tolerated
tools for the prevention of AF after on pump coronary artery bypass surgery.
Patients and methods: The study included 176 patients (age range 40 to 79 years) and
scheduled for elective on pump CABG operations without concomitant procedures. The patients
were divided randomly into two equal groups. Group (A) in which bisoprolol was used for
prophylaxis against atrial fibrillation after surgery. Group (B) in which bisoprolol and
hydrocortisone were used for prophylaxis against atrial fibrillation after surgery. For each
patient, the following data were collected: gender, preoperative diseases, intraoperative
cross clamp time, cardiopulmonary bypass time, and Lt internal mammary Artery usage,
incidence of postoperative atrial fibrillation, death, myocardial infarction chest infection
and C - reactive protein levels.
The study was conducted at The Cardiothoracic surgery intensive care unit of Ain Shams
University hospitals during a period of 6 months. The study protocol was approved by
"research and ethics committee" of anesthesia and intensive care department, Ain Shams
University. Informative consent was obtained from the patients before enrolling in the study.
176 Patients were registered in the study. Patients were randomly allocated by
computer-generated random number list into two study groups of 88 patients each, with a range
of age between 40 and 79 years old and were undergoing elective on pump CABG operations
without concomitant procedures.
Group A:
Patients received bisoprolol 5mg per oral (P.O.) in the evening of the operation and then one
dose (5 mg) every twenty four hours during the next two days.
Group B:
Patients received bisoprolol as group (A) in addition hydrocortisone 100 mg intravenously is
given in the evening of the operation and then 100 mg every eight hours during the next two
days.
Exclusion criteria for the study included: Patients with preoperative rhythm abnormalities
(sick sinus syndrome, atrioventricular conduction abnormalities, history of chronic or
intermittent AF), pretreatment with classes I and III antiarrhythmic agents, receiving
anti-hypertensive drugs except angiotensin convertor enzyme (ACE) inhibitors, thyroid
disease, renal or liver disease, peripheral arterial atherosclerotic disease,
thrombophlebitis, uncontrolled diabetes mellitus, systemic bacterial or mycotic infection,
active tuberculosis, Cushing's syndrome, peptic ulcer, psychotic mental disorder, Herpes
Simplex keratitis and chronic obstructive pulmonary disease were not included in the study.
Intraoperative technique:
After sedation with diazepam (10 mg intramuscular), radial arterial catheterization,
intravenous catheters, and a central venous catheter were introduced in the operating
theater. Hemodynamic parameters; Heart rate monitoring, mean arterial pressure, rectal
temperature, central venous pressure and arterial blood gas throughout the process was
observed. Anesthesia was started by fentanyl (35 mg / kg) and muscle relaxation was achieved
with pancronium (0.1 mg / kg), then endotracheal intubation using ventilation with 100%
oxygen. The median incision of the sternum was used for cardiac exposure. The left internal
mammary artery was harvested and the saphenous vein was prepared, if necessary. All
operations were performed under cardiopulmonary bypass and moderate hypothermia (28-328C)
with flow rates of 2.2-2.4 l / m2 and the mean perfusion pressure of 50-85 mm Hg. Heart
failure was assisted by initial crystalloid cardioplegia (48C, 15 cc / kg) and heart
preservation was assisted with 400 cc cold blood Cardioplegia every 20 minutes. The hot shut
was performed shortly before removing the cross clamp. The venous cannula was inserted
through the right atrial appendix. The arterial cannula was placed in the ascending aorta.
2.3. Postoperative Monitoring: All patients were continuously monitored at the ICU with
electrocardiography (ECG), invasive blood pressure and with finger probe for oxygen
saturation within 48 h.
Patients developed atrial fibrillation received treatment according to their condition, if
they are haemodynamically unstable electrical cardioversion (synchronized adjusted at 100
joules using biphasic electrical cardiovertor) was applied. If they are haemodynamically
stable pharmacological cardioversion (amiodarone 5 mg/kg intravenous over 60 minutes, then
1.2 grams per day by continuous intravenous infusion) was used. (5)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |